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Abstract
Background
The second wave of avian influenza H7N9 virus outbreak in humans spread to the Guang-
dong province of China by August of 2013 and this virus is now endemic in poultry in
this region.
Methods
Five patients with H7N9 virus infection admitted to our hospital during August 2013 to Feb-
ruary 2014 were intensively investigated. Viral load in the respiratory tract was determined
by quantitative polymerase chain reaction (Q-PCR) and cytokine levels were measured by
bead-based flow cytometery.
Results
Four patients survived and one died. Viral load in different clinical specimens was correlated
with cytokine levels in plasma and broncho-alveolar fluid (BALF), therapeutic modalities
used and clinical outcome. Intravenous zanamivir appeared to be better than peramivir as
salvage therapy in patients who failed to respond to oseltamivir. Higher and more prolonged
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viral load was found in the sputum or endotracheal aspirates compared to throat swabs.
Upregulation of proinflammatory cytokines IP-10, MCP-1, MIG, MIP-1α/β, IL-1β and IL-8
was found in the plasma and BALF samples. The levels of cytokines in the plasma and viral
load were correlated with disease severity. Reactivation of herpes simplex virus type 1
(HSV-1) was found in three out of five patients (60%).
Conclusion
Expectorated sputum or endotracheal aspirate specimens are preferable to throat swabs
for detecting and monitoring H7N9 virus. Severity of the disease was correlated to the viral
load in the respiratory tract as well as the extents of cytokinemia. Reactivation of HSV-1
may contribute to clinical outcome.
Introduction
A novel avian H7N9 influenza A virus emerged in March of 2013 causing serious human dis-
ease and death in China [1,2]. Up to 5 May 2014, 432 confirmed human cases leading to more
than 160 deaths have been reported (http://www.cnic.org.cn/uploadfile/2014/0513/
20140513031342659.pdf). While the initial outbreak of the H7N9 in humans occurred around
the Yangtze River delta in March and April 2013, the infection spread in poultry to South
China and the second wave of the epidemic affected South of China including Guangdong and
Hong Kong, in the winter of 2013 [3,4]. During the first wave of outbreak, the majority of the
reported cases of A/H7N9 disease were patients with fulminant viral pneumonia, identified
through the national surveillance system for pneumonia of unknown etiology [5]. In the re-
ported case series, A/H7N9 patients typically developed a rapidly progressive viral pneumonia
leading to respiratory failure and acute respiratory distress syndrome (ARDS) reminiscent of
human HPAI H5N1 disease [2,3,6,7].
There are now over 102 A/H7N9 cases reported within Guangdong Provence since August
of 2013 suggesting that this region is now endemic for A/H7N9 virus. The numbers of new
cases appear to be increasing recently. Cases identified in Hong Kong were also probably ac-
quired infection through contact with live poultry in Guangdong Province [4]. Detailed study
on the viral loads, cytokines and clinical outcome on patients infected by the re-emergent
H7N9 strain is still lacking.
In this study, we summarized the clinical manifestations and disease progression of five pa-
tients who were infected with the H7N9 viruses in Guangdong Province. We correlated their
disease progression and clinical outcome with viral load and cytokine levels in plasma. The ef-
fect of neuraminidase inhibitors and convalescent plasma therapy was also investigated.
Materials and Methods
Patients
Five consecutive patients diagnosed as laboratory-confirmed avian influenza A (H7N9) virus
infection at the First Affiliated Hospital of Guangzhou Medical University were included in
this study. All patients initially presented at local primary health care clinics or local hospitals
before they were referred to the Intensive Care Unit (ICU) of the First Affiliated Hospital of
Guangzhou Medical University. At the time of enrolment and hospitalization, the subject’s
clinical history, physical examination, radiological findings, hematological, biochemical and
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microbiological investigations were recorded. We defined acute respiratory distress syndrome
on the basis of the Berlin Definition [8]. Presumed incubation period was defined as the time
between last poultry exposure and the onset of symptoms. Approval for the study was obtained
from the ethics committee of the First Affiliated Hospital of Guangzhou Medical University
and written informed consent was obtained from the patients or their family members
Detection of virus infection and viral load
Throat swabs, conjunctival swab, bronchoalveolar lavage fluid (BALF), sputum, endotracheal
aspirate, urine, and/or fecal samples were collected from the day of admission to ICU through-
out the period of hospitalization. The viral RNA from the samples was extracted using QIAamp
MinElute Virus Spin kit (Qiagen, Valencia, USA) according to the manufacturer’s instructions.
Avian influenza A(H7N9) virus was detected using the avian influenza A virus H7N9 Real
Time RT-PCR kit (Shanghai ZJ Bio-tech Co., Ltd., Shanghai, China) which has approved by
the Chinese Food and Drugs Agency. Viral RNA concentration was quantified by real-time
PCR in parallel with standards with a known copy numbers of the haemagglutinin gene cloned
in a plasmid. Viral load was inferred as copy numbers per ml of samples in the lysis buffer.
Viral DNA was extracted by the QIAamp DNAMini Kit (Qiagen) for detection of HSV-1 by
PCR and the viral load was inferred as ΔCT value.
Detection of cytokine levels
Cytokines (IL-8, IP-10, interferon-α, MIP-1α, MIP-1β, MCP-1, MIG, IL-1β) from the BALF
and plasma samples of the patients was determined using a CBA human inflammatory cyto-
kine kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions.
Data acquisition was performed on BD LSR Fortessa (BD Biosciences). Data were analyzed by
CBA analysis software.
Serology test
Titers of anti-H7N9 influenza antibody were measured by hemagglutination inhibition (HI)
assay and microneutralization-ELISA (micro NT-ELISA) assays according to the WHO proto-
cols [9, 10]. Horse red blood cells were used in the HI assay. A/Anhui/01/2013 H7N9 virus was
used as the reference antigen or virus for the serology tests. All bioassays were conducted in a
BSL-3 laboratory.
Results
The first five patients admitted to our intensive care unit, from August 2013 to February 2014,
were included in this study and this includes the first human case of H7N9 infection in Guang-
dong province (Patient 1). The age of the patients ranged from 39 to 66 years. Four of the pa-
tients survived and were discharged from hospital finally while one patient (Patient 3) died.
Four of them had exposure history to live poultry within 14 days of onset of clinical symptoms.
The demographic characteristics are shown in supplementary table 1 (S1 Table) and the radio-
logical findings at the day of admission are shown in supplementary figure 2 (S2 Fig.).
Fever38.5°C, fatigue, cough, sputum production and shortness of breath were reported by
the five patients at the onset of illness but there was no evidence of conjunctivitis (Table 1) and
virus was not detected in any of the conjunctival swabs tested. Once they were confirmed to
have H7N9 infection, all the patients were commenced on 150 mg of oseltamivir twice daily.
Meropenem (1g, bid), Vancomycin (500mg, tid) or Tienam (1g tid) were generally used as the
first line of antibiotic treatment according to community-acquired pneumonia guidelines [11].
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Antiviral therapy was altered in the event of non-response to the initial antiviral regimen. The
type and the dosages of the drugs given to patients 1 to 5 during hospitalization is summarized
in supplementary table 2 (S2 Table).
Patient 1 had pneumonia and acute respiratory distress syndrome (ARDS) at admission to
the ICU (day 9 after disease onset). Her APACHEII score was 10 at the first day in ICU. Com-
mencement of oseltamivir treatment was associated with a fall of viral load from the throat and
BALF samples, turning negative at day 16 post illness and was associated with increasing of ox-
ygen index (Fig. 1A). Decreasing levels of pro-inflammatory cytokines in plasma were observed
(Fig. 1E).
Both patient 2 and 3 developed ARDS accompanied by shock. Their APACHEII score were
15 and 19 respectively at the first day in ICU. High total leukocyte and neutrophils counts were
found in peripheral blood suggesting that secondary bacterial infection had already occurred
(S3 Table). Additional antibiotics were therefore given (S2 Table). While the leukocyte counts
returned to normal ranges in patient 2 after 20 days of the disease onset, leukocyte counts in
patient 3 remained elevated throughout hospitalization. However, no bacteria could be cul-
tured from the sputum or BALF samples in either patient. Their fecal specimens and plasma
Table 1. Clinical symptoms, complications, treatment, and clinical Outcomes.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
APACHE II score 10 15 19 10 3
Clinical symptoms
Fever Yes Yes Yes Yes Yes
Maximal temperature (℃) 39.5 38.7 39.4 40.5 39.9
Fatigue Yes Yes Yes Yes Yes
Cough Yes Yes Yes Yes Yes
Sputum production Yes Yes Yes Yes Yes
Hemoptysis No No No Yes No
Shortness of breath Yes Yes Yes Yes Yes
Diarrhea or vomiting Yes No No No No
Conjunctivitis No No No No No
Complications
Pneumonia Yes Yes Yes Yes Yes
Acute respiratory distress syndrome Yes Yes Yes Yes Yes
Shock No Yes Yes No No
Acute kidney injury No No Yes No No
Rhabdomyolysis No No No No No
Bacteria isolation from culture No No No No No
Treatment
Antiviral drugs Yes Yes Yes Yes Yes
Oxygen therapy Yes Yes Yes Yes Yes
Extracorporealmembrane oxygenation No No Yes No No
Mechanical ventilation Invasive Invasive Invasive Noninvasive Noninvasive
Continuous renal-replacement therapy No No Yes No No
Antibiotics Yes Yes Yes Yes Yes
Antifungal drugs Yes Yes Yes Yes No
Glucocorticoids Yes Yes Yes No No
Intravenous immune globulin Yes Yes Yes No No
Clinical outcome Discharged Discharged Death Discharged Discharged
doi:10.1371/journal.pone.0117846.t001
Patients Infected with Re-Emergent H7N9 Disease
PLOS ONE | DOI:10.1371/journal.pone.0117846 February 27, 2015 4 / 11
Fig 1. Viral load and oxygen index in different clinical specimens, (A-D, I) and plasma cytokine levels (F-H) in H7N9-infected patients. Patient 1 (A,
E); Patient 2 (B, F); Patient 3 (C, G); Patient 4 (D, H); Patient 5 (I). The commencement of antiviral drugs oseltamivir, and where relevant, peramivir,
intravenous zanamivir or convalescent plasma is indicated in Figs. A-D, I).
doi:10.1371/journal.pone.0117846.g001
Table 2. Detection of HSV-1 from the patients.
Patient 2 Patient 3 Patient 4
Days of
disease onset
CT value (type of
specimen)
Days of
disease onset
CT value (type of specimen) Days of
disease onset
CT value (type of
specimen)
23 HSV-35.02 (throat
swab)
23 HSV-30.63 (throat swab) 13 HSV-33.67 (throat
swab);
24 HSV-26.85 (throat swab) 16 HSV-31.73 (ETA)
25 HSV-33.47 (throat swab)
26 HSV-24.15 (throat swab)
27 HSV-23.07 (throat swab)
28 HSV-24.73 (throat swab)
29 HSV-18.05 (throat swab)
31 HSV-17.74 (throat swab); HSV-30.35 (sputum
from lower lung); HSV-32.02 (plasma)
doi:10.1371/journal.pone.0117846.t002
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was also collected at these time points but were all negative for H7N9 RNA by RT-PCR. The
viral load remained at 105 to 104 copies per ml in BALF specimens although both patients had
been given oseltamivir for three to five days (Fig. 1B and C). No oseltamivir resistant mutations
(neuraminidase gene R292K) were found from the H7N9 NA gene amplified by PCR (data not
shown). Changing the antiviral drug to peramivir did not suppress H7N9 viral load but subse-
quent change to intravenous zanamivir was associated with a rapid decrease in the viral load in
patient 2 (Fig. 1B). This was also associated with progressive improvement in the oxygen
index. HSV-1 DNA (CT value 35.02) was identified from the throat specimen of patient 2 at
day 23 after the disease onset (Table 2). IP-10 was the predominant plasma cytokine detected
in the early days post admission (Fig. 1F). Interestingly, concentrations of MIG were much
higher in the BALF than in plasma while IL-8 was only detectable in the BALF (Table 3).
In patient 3, neither oseltamivir, peramivir nor intravenous zanamivir was associated with sup-
pression of H7N9 viral load in the sputum of endotracheal aspirate (around 103 to 104 viral copies
per ml) although the throat swab became negative on day 23 post disease onset. Because of his ad-
verse clinical condition and lack of response to all three antiviral drugs, one dose of convalescent
plasma which had been collected from a recovered H7N9 patient was injected intravenously at day
20 after his disease onset. There was no improvement in the oxygen index even after the com-
mencement of intravenous immune globulin (Fig. 1C). This patient already had H7N9 antibody ti-
ters of 1:320 by the HI test and 1:160 by the microneutraliation test prior to the therapy with
convalescent plasma. There was an increase in neutralizing antibody titer to H7N9 was detected in
his serum immediately after the injection of convalescent plasma (S1 Fig.). The plasma levels of IP-
10 remained elevated to levels higher than seen in patients 1 or 2 through day 22–26 of illness and
there was a further dramatic increase of plasmaMIG andMCP-1 on day 29–30 (Fig. 1G). There
were very high levels of IL-8 in BALF that was not detected in plasma (Table 3). The patient died
from sepsis with multi-organ failure at day 32 after disease onset [12]. Importantly, he had detect-
able HSVDNA in the throat swabs from day 23 post onset (CT 30.63) and the viral load progres-
sively increased (CT 18.05) by day 29 of illness. At this time (day 31 post onset) HSVDNAwas
also detected in sputum (CT value 30.35) and plasma (CT value 32.02) (Table 2). These HSV PCR
results were only available in retrospect and these patients were not treated with acyclovir.
Patient 4 and 5 were less severely ill at presentation with an oxygen index of around 150 to
400. Their APACHEII scores were 10 and 3 respectively, on the first day in ICU. No intubation
was required but only non-invasive nasal mask ventilation was given during hospitalization. They
were commenced on oseltamivir on day 11 (Patient 4) and day 4 (Patient 5) of illness, respectively.
H7N9 RNA detection from their throat swabs was positive only for one day after hospitalization
(day 12 and day 11 of disease onset, respectively). However, virus remained detectable in their
sputum specimens for much longer until day 20 of illness. Faecal and plasma specimens remained
negative for viral RNA. Increasing oxygen index was seen following the commencement of oselta-
mivir (Fig. 1D and I). Pro-inflammatory cytokines in plasma of patient 4 were also not very high
and gradually declined with the reducing viral load (Fig. 1H). Reactivation of HSV was identified
from the throat and ETA samples of patient 4 on day 13 and 16 after disease onset (Table 2).
Discussion
We compared and summarized the serial H7N9 viral load in throat swab, sputum, endotrache-
al aspirates and BALF; with plasma and (in patients 2 and 3) BALF cytokine levels and with ox-
ygen index and clinical outcome of patients with differing clinical severity. These data have
been correlated with antiviral (oseltamivir, peramivir and intravenous zanamivir) therapy and
in one patient with the effects of intravenous therapy with convalescent plasma. The serial viral
neutralization and HI antibody titers are also reported. All patients had a history of exposure
Patients Infected with Re-Emergent H7N9 Disease
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to poultry suggesting that these may be zoonotic infections from poultry. The initial clinical
symptoms of the patients were similar to that previously reported with fever, fatigue, cough,
sputum production and shortness of breath being the common early clinical features [6]. Viral
load detected from sputum, which can be obtained from non-intubated patients, provided
comparable sensitivity to the BALF or ETA and was superior to throat swabs. The serial viral
load data shows that clearance of virus from throat swab specimens is not a reliable index ther-
apeutic success. This was most clearly seen with patients 2 and 3 where virus in throat swabs
became undetectable although virus remained at high titer in deep respiratory specimens (spu-
tum, endotracheal aspirate, BALF), indicating lack of virological response which correlated
with clinical outcome. In patient 2, throat swab viral load falsely suggested response to oselta-
mivir or peramivir therapy although deep respiratory specimens endotracheal aspirate, spu-
tum, BALF) did not. The viral load in deep respiratory specimens correlated better with the
oxygen index, showing that intravenous zanamivir led to virus clearance and clinical improve-
ment. In patient 3, the throat swab viral load again falsely suggested H7N9 virus clearance asso-
ciated with antiviral therapy although virus continued to be detected in sputum and
endotracheal aspirates with poor oxygenation and this patient had a fatal outcome.
The antiviral effect of oseltamivir varies among the patients although it is still our front line
anti-viral drug given to the patients with H7N9 infection. We observed that oseltamivir therapy
was associated falling viral load and clinical response in patients 1, 4 and 5 even though they
were commenced on therapy in the second week of illness. By the time oseltamivir therapy was
commenced, these three patients were also mounting neutralizing and HI antibody responses to
H7N9. Thus it is not clear whether they were responding to the antiviral therapy or were clear-
ing the virus via their own adaptive immune responses. Peramivir did not appear to be effective
salvage therapy for patients 2 and 3 who failed to respond virologically and clinically to
Table 3. Comparison of the cytokine levels (pg/ml) from plasma and BAL.
Days after onset 8 9 11 13 15
Patient 2 Plasma BALF Plasma BALF Plasma BALF Plasma BALF Plasma BALF
IP-10 15970.4 4302.5 4402.4 958.5 1407.3 61.8 732.1 3058.3 497.7 1097.8
IL-8 30.0 153.8 17.3 733.6 26.4 852.0 16.5 2485.4 11.3 958.7
MCP-1 606.0 0.0 55.9 320.9 325.9 0.0 206.8 6522.5 45.2 44.7
MIG 0.0 7859.8 473.8 92.5 186.8 30.7 269.7 591.5 227.4 1046.2
MIP-12 2.8 35.6 1.6 0.0 1.4 0.0 1.3 0.0 0.0 13.0
MIP-12 62.6 0.0 57.3 14.2 71.0 0.0 24.2 43.7 2.5 14.7
IFN- 9.1 23.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
IL-1 2 0.0 0.0 0.0 0.0 0.0 48.4 0.0 0.0 0.0 0.0
Days after onset 15 16 18
Patient 3 Plasma BALF Plasma BALF Plasma BALF
IP-10 217.8 110.7 179.4 644.0 400.7 832.2
IL-8 0.0 5275.5 0.0 5404.4 0.0 29.3
MCP-1 0.0 40.6 1.9 41.1 17.3 0.0
MIG 53.3 306.7 48.6 1253.2 114.4 339.1
MIP-1 0.0 21.9 0.0 154.9 0.0 11.8
MIP-1 0.0 29.0 0.0 22.4 0.0 0.0
IFN- 0.0 0.0 0.0 0.0 0.0 0.0
IL-1 0.0 185.2 0.0 394.4 0.0 12.5
doi:10.1371/journal.pone.0117846.t003
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oseltamivir. However, intravenous zanamivir was associated with virological and clinical re-
sponse in patient 2 but not in patient 3. Autopsy results showed that the pulmonary alveoli were
partially collapsed in patient 3, with atypical hyperplasia and greater prominence of nuclei in
pulmonary alveolar epithelial cell (unpublished data). The presence of squamous metaplasia of
the bronchial epithelium, interstitial fibrous tissue hyperplasia and lymphocyte infiltration were
identified in lung. Such pathological changes were in accordance with interstitial pneumonia ac-
companied by alveolar epithelial atypical adenomatous hyperplasia. Taken the factors together
including pathologic changes, long persistence of viral shedding, and HSV infection, immune-
suppression may exist and contribute to severe disease outcome of patient 3. However, whether
this was the reason that patient 3 was irresponsive to the antiviral treatment is not clear.
It has been reported that treatment of severe H1N1 2009 infection with convalescent plasma
reduced respiratory tract viral load, serum cytokine response, and mortality [13]. However, in
patient 3, one dose of convalescent plasma from a patient who had recovered from H7N9 dis-
ease failed to reduce viral load in the sputum or endotracheal aspirate and had no beneficial
clinical effect on oxygenation. By the time that convalescent plasma was administered to this
patient (day 20 of illness), there was already a good HI and neutralizing antibody response. Al-
though the plasma infusion was associated with a transient increase in the neutralizing anti-
body response, it may have been too late in the clinical course to effect clinical benefit. Another
possibility is that no enough convalescent plasma for following use, leading to its clinical bene-
fit unclear. Earlier intervention may have been more beneficial but the challenge is to identify
those patients who will fail to respond to antiviral therapy early enough. Alternatively, it may
be those patients who fail to make robust neutralizing antibody titers by day 10 of illness who
may benefit most from passive antibody therapy [14]
Secondary bacterial infection is known to be an important cause of poor clinical outcome in
influenza, including that caused by the pandemic H1N1 virus or H7N9 virus. [15–19]. In our
therapeutic strategy, antibiotics were first given to the patients in the local hospitals according
to community-acquired pneumonia guideline. In severe cases, additional antibiotics and anti-
fungal therapy was administered. Although the prescribing of antibiotics may be associated
with side effects and may increase antibiotic resistance, our primary aim is to reduce the risk of
secondary infection in order to increase the patient survival rate. However, both patient 2 and
3 still showed evidence suggestive of secondary bacterial infection as reflected by their increas-
ing white cell and neutrophil cell count in the blood. We suspect that bacterial infection may
have existed before admission to our hospital.
Hypercytokinemia has been noted as a factor associated with adverse clinical outcome dur-
ing influenza infection [19–21]. One study showed that the plasma levels of IL-6 and IP-10 in
severe cases are higher than the non-severe cases [22], while another study found that IL-6, IL-
8 and to a lesser extent, MIP-1β and IL-10 production was higher in fatal than the non-fatal
cases [23]. Overall, we found the cytokine levels in plasma samples were substantially higher in
the fatal case than the three survival cases (Fig. 1E to H) and the cytokine levels in the plasma
samples of the survived patients declined along with the improvement of their condition while
dramatic increase of cytokines were observed in patient 3 before he died. We found that fatal
patient had much higher plasma levels of IL-8, IP-10, MCP-1, MIG and MIP-1β, and higher
BALF levels of IL-1β and IL-8, compared to the survivors.
The levels of cytokines in the concurrent plasma and BALF samples showed remarkable dif-
ferences. Some cytokines such as IL-8 were only elevated in BALF and high levels were noted
in the BALF of the patient 3 (with fatal outcome) as early as day 15 of illness with moderate lev-
els also seen in severely ill patient 2. Elevated level of IL-1β was only detectable in BALF. Levels
of other chemokines such as IP-10 were as high or higher in the plasma compared to the
BALF. Wang and colleagues also reported markedly different cytokine levels between plasma
Patients Infected with Re-Emergent H7N9 Disease
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and BALF samples in fatal patients and that IL-8 was mainly detected in BALF samples [19].
Whether IL-8 in BALF is a maker associated secondary bacterial infection (which patients 2
and 3 probably had) or whether it is an independent marker of adverse clinical outcome de-
serves further study. Some cytokines such as IP-10, MCP-1 and MIG which have been associat-
ed to the pathogenicity of avian H7N9 influenza virus infection in humans [24] were not tested
for in the study byWang et al [23]. Our results compared the induction of these three cytokines
in BALF vs. plasma between fatal and non-fatal patients. The levels of these cytokine in the
BALF of fatal patient are generally higher than the corresponded plasma samples. The level of
IP-10 and MCP-1 were higher in plasma than in BALF at the early disease onset of the non-
fatal patient but an opposite trend was observed with the improvement of her condition.
In summary, our serial viral load, cytokine data and clinical outcome from 5 intensively inves-
tigated patients with diverse clinical outcome provide some insights for the monitoring and clini-
cal management of patients with H7N9 disease. Deep respiratory specimens such as sputum or
ETA specimens rather than throat swabs are crucial for monitoring the clinical response to thera-
py and likely for initial diagnosis as well. Long persistence of viral shedding in mild cases should
attract people’s attention for progressing severe disease. Although our patient numbers are limit-
ed, peramivir does not appear to have any impact in salvage therapy of patients who fail to re-
spond to oseltamvir, even in the absence of the NA R292Kmutation while intravenous zanamivir
appears to be more useful in this regard. A study is needed to prospectively compare the particular
regimen was associated with superior outcomes or reduced emergence of resistance.
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